| SCHEDULE OF SEGMENT INFORMATION |
As
of March 31, 2026, the Company currently has the following reportable segments: Homology of Medicine and Food Series, Computing Power
Product Series, Maca Product Series and others.
SCHEDULE
OF SEGMENT INFORMATION
| | |
Series | | |
Series | | |
Series | | |
Costs | | |
Total | |
| | |
Six months ended March 31, 2026 | |
| | |
Business Line | | |
Others | | |
| |
| | |
Homology of Medicine and Food | | |
Computing Power Product | | |
Maca Product | | |
Unallocated Headquarter | | |
| |
| | |
Series | | |
Series | | |
Series | | |
Costs | | |
Total | |
| Revenues, net | |
$ | 1,855,618 | | |
$ | 5,010,158 | | |
$ | 12,118,011 | | |
$ | - | | |
$ | 18,983,787 | |
| Cost of revenue | |
| (1,830,086 | ) | |
| (4,933,945 | ) | |
| (12,118,589 | ) | |
| (98 | ) | |
| (18,882,718 | ) |
| Gross profit | |
| 25,532 | | |
| 76,213 | | |
| (578 | ) | |
| (98 | ) | |
| 101,069 | |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| Operating expenses | |
| (47,537 | ) | |
| (86,256 | ) | |
| (270,238 | ) | |
| (3,013,749 | ) | |
| (3,417,780 | ) |
| Loss from operations | |
| (22,005 | ) | |
| (10,043 | ) | |
| (270,816 | ) | |
| (3,013,847 | ) | |
| (3,316,711 | ) |
| | |
| | | |
| | | |
| | | |
| | | |
| | |
| Fair value variation | |
| - | | |
| - | | |
| - | | |
| (31,633,746 | ) | |
| (31,633,746 | ) |
| Gain on disposal of subsidiary | |
| - | | |
| - | | |
| - | | |
| 19,824 | | |
| 19,824 | |
| Other income | |
| 155 | | |
| 178 | | |
| 1,654 | | |
| 75,059 | | |
| 77,046 | |
| Other expense | |
| (8 | ) | |
| (13 | ) | |
| (90 | ) | |
| (7,212 | ) | |
| (7,323 | ) |
| Segment Loss | |
$ | (21,858 | ) | |
| (9,878 | ) | |
| (269,252 | ) | |
| (34,559,922 | ) | |
| (34,860,910 | ) |
|